Sarepta Therapeutics eta Rocheren farmazeutikoak, Duchenneko muskulu-distrofiaren (DMD) inguruko tratamendu bat frogatzeko saiakuntza kliniko bat egiten ari dira lehenengoz Europan Bartzelonako Sant Joan de Déu (SJD) ospitalean. Gehiago ikusi
Sarepta Therapeutics has executed an exclusive license agreement for a gene therapy candidate that aims to treat limb-girdle muscular dystrophy type 2A (LGMD2A), the company announced.
The investigational therapy, called calpain 3 or CAPN-3, was developed at the Abigail Wexner Research Institute at Nationwide Children’s Hospital, in Columbus, Ohio.
The deal followed a number of successful preclinical and safety studies led by Zarife Sahenk, MD, PhD, an attending neurologist at the hospital.